Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2002

01-11-2002 | Original article

A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia

Authors: John Panetta, Yuri Yanishevski, Ching-Hon Pui, John T. Sandlund, Jeffrey Rubnitz, Gaston K. Rivera, Raul Ribeiro, William E. Evans, Mary V. Relling

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2002

Login to get access
Metadata
Title
A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia
Authors
John Panetta
Yuri Yanishevski
Ching-Hon Pui
John T. Sandlund
Jeffrey Rubnitz
Gaston K. Rivera
Raul Ribeiro
William E. Evans
Mary V. Relling
Publication date
01-11-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0511-x

Other articles of this Issue 5/2002

Cancer Chemotherapy and Pharmacology 5/2002 Go to the issue

Review

Current status of the molecular mechanisms of anticancer drug-induced apoptosis

Original Article

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

Original Article

Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model

Original Article

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

Original Article

Angiostatin potentiates cyclophosphamide treatment of metastatic disease

Original Article

Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits